These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 37919903)
1. A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Lee IK; Sharma N; Noguera-Ortega E; Liousia M; Baroja ML; Etersque JM; Pham J; Sarkar S; Carreno BM; Linette GP; Puré E; Albelda SM; Sellmyer MA Mol Ther; 2023 Dec; 31(12):3564-3578. PubMed ID: 37919903 [TBL] [Abstract][Full Text] [Related]
2. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Sellmyer MA; Richman SA; Lohith K; Hou C; Weng CC; Mach RH; O'Connor RS; Milone MC; Farwell MD Mol Ther; 2020 Jan; 28(1):42-51. PubMed ID: 31668558 [TBL] [Abstract][Full Text] [Related]
4. Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand. Sun J; Zhang W; Zhao Y; Liu J; Wang F; Han Y; Jiang M; Li S; Tang D Cytotherapy; 2021 Dec; 23(12):1085-1096. PubMed ID: 34593327 [TBL] [Abstract][Full Text] [Related]
5. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180 [TBL] [Abstract][Full Text] [Related]
6. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography. Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798 [TBL] [Abstract][Full Text] [Related]
7. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368 [TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Maus MV; Levine BL Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942 [TBL] [Abstract][Full Text] [Related]
9. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering. Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559 [TBL] [Abstract][Full Text] [Related]
10. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. Darowski D; Kobold S; Jost C; Klein C MAbs; 2019; 11(4):621-631. PubMed ID: 30892136 [TBL] [Abstract][Full Text] [Related]
11. A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology. Lee SM; Kang CH; Choi SU; Kim Y; Hwang JY; Jeong HG; Park CH ACS Synth Biol; 2020 May; 9(5):987-992. PubMed ID: 32352759 [TBL] [Abstract][Full Text] [Related]
12. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies. Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322 [TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations. Brookens SK; Posey AD Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155 [TBL] [Abstract][Full Text] [Related]
14. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771 [TBL] [Abstract][Full Text] [Related]
15. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. Zhang E; Xu H J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484 [TBL] [Abstract][Full Text] [Related]
16. Advances in modular control of CAR-T therapy with adapter-mediated CARs. McCue AC; Yao Z; Kuhlman B Adv Drug Deliv Rev; 2022 Aug; 187():114358. PubMed ID: 35618140 [TBL] [Abstract][Full Text] [Related]
17. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Jindal V; Arora E; Gupta S Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801 [TBL] [Abstract][Full Text] [Related]
18. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729 [TBL] [Abstract][Full Text] [Related]
19. An in vivo covalent TMP-tag based on proximity-induced reactivity. Gallagher SS; Sable JE; Sheetz MP; Cornish VW ACS Chem Biol; 2009 Jul; 4(7):547-56. PubMed ID: 19492849 [TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]